Experienced in Asymptomatic Bacteriuria

Dr. Emily A. Blumberg

Infectious Disease
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
39 Years of Experience
Experienced in Asymptomatic Bacteriuria
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emily Blumberg is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Blumberg has been practicing medicine for over 39 years and is rated as an Experienced provider by MediFind in the treatment of Asymptomatic Bacteriuria. Her top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, HIV/AIDS, and Hepatitis C. Dr. Blumberg is currently accepting new patients.

Her clinical research consists of co-authoring 167 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
New York University
Residency
University of Chicago Medical Center
Specialties
Infectious Disease
Licenses
Internal Medicine in PA
Board Certifications
Internal Medicine, 1984
Fellowships
Albert Einstein - Montefiore Medical Center
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Languages Spoken
English
Gender
Female
Awards
Recognized annually in Philadelphia magazine's Top Docs issue from 2011 through 2025

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

MacGregor Infection Medicine and Travel Program
3400 Civic Center Boulevard, South Pavilion, 4th Floor, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients
A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19
Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19
Enrollment Status: Completed
Publish Date: January 11, 2022
Intervention Type: Drug
Study Drug: Cyclosporine
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 4
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
Enrollment Status: Completed
Publish Date: November 01, 2019
View 8 Less Clinical Trials

167 Total Publications

APOL1 genotype and patient outcomes in US and South African transplant recipients with HIV who received kidneys from donors with HIV.
APOL1 genotype and patient outcomes in US and South African transplant recipients with HIV who received kidneys from donors with HIV.
Journal: medRxiv : the preprint server for health sciences
Published: May 05, 2025
Similar Doctors
Distinguished in Asymptomatic Bacteriuria
Dr. Margaret U. Chung
Infectious Disease
Distinguished in Asymptomatic Bacteriuria
Dr. Margaret U. Chung
Infectious Disease
20 Hospital Dr, 
Toms River, NJ 
 (51.7 miles away)
732-797-1979
Languages Spoken:
English
See accepted insurances

Margaret Chung is an Infectious Disease provider in Toms River, New Jersey. Dr. Chung is rated as an Advanced provider by MediFind in the treatment of Asymptomatic Bacteriuria. Her top areas of expertise are Asymptomatic Bacteriuria, Methicillin-Resistant Staphylococcus Aureus (MRSA), Strep Throat, and Pneumonia.

Advanced in Asymptomatic Bacteriuria
Dr. Mitchell P. Sternlieb
Infectious Disease
Advanced in Asymptomatic Bacteriuria
Dr. Mitchell P. Sternlieb
Infectious Disease

Delaware Valley I.D. Associates, P.C.

100 E Lancaster Ave, Suite 467, 
Wynnewood, PA 
 (4.6 miles away)
610-896-0210
Languages Spoken:
English
See accepted insurances

Mitchell Sternlieb is an Infectious Disease provider in Wynnewood, Pennsylvania. Dr. Sternlieb is rated as a Distinguished provider by MediFind in the treatment of Asymptomatic Bacteriuria. His top areas of expertise are Sepsis, Infective Endocarditis, Hospital-Acquired Pneumonia, and Pneumonia.

Distinguished in Asymptomatic Bacteriuria
Dr. Natalia Raoof
Infectious Disease
Distinguished in Asymptomatic Bacteriuria
Dr. Natalia Raoof
Infectious Disease

Id Care LLC

105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
 (47.5 miles away)
908-281-0221
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Natalia Raoof is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Raoof is rated as a Distinguished provider by MediFind in the treatment of Asymptomatic Bacteriuria. Her top areas of expertise are Pneumonia, Hospital-Acquired Pneumonia, Multisystem Inflammatory Syndrome in Children (MIS-C), and COVID-19. Dr. Raoof is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blumberg's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile